AbbVie Historical Cash Flow
| ABBV Stock | USD 181.77 1.16 0.63% |
Analysis of AbbVie cash flow over time is an excellent tool to project AbbVie Inc future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Stock Based Compensation of 428.3 M or Free Cash Flow of 12 B as it is a great indicator of AbbVie ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining AbbVie Inc latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether AbbVie Inc is a good buy for the upcoming year.
AbbVie |
About AbbVie Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in AbbVie balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which AbbVie's non-liquid assets can be easily converted into cash.
AbbVie Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by AbbVie Inc to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of AbbVie operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Dividends Paid
The total amount of dividends that a company has paid out to its shareholders over a specific period.Most accounts from AbbVie's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into AbbVie Inc current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AbbVie Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. At this time, AbbVie's Change In Cash is fairly stable compared to the past year. Change In Working Capital is likely to climb to about 3 B in 2024, whereas Stock Based Compensation is likely to drop slightly above 428.3 M in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Free Cash Flow | 22.0B | 24.2B | 22.1B | 12.0B | Stock Based Compensation | 692M | 671M | 747M | 428.3M |
AbbVie cash flow statement Correlations
Click cells to compare fundamentals
AbbVie Account Relationship Matchups
High Positive Relationship
High Negative Relationship
AbbVie cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (231M) | (40M) | (142M) | (686M) | (417M) | (396.2M) | |
| Change In Cash | 32.6B | (31.5B) | 1.3B | (545M) | 3.6B | 3.8B | |
| Stock Based Compensation | 430M | 753M | 692M | 671M | 747M | 428.3M | |
| Free Cash Flow | 12.8B | 16.8B | 22.0B | 24.2B | 22.1B | 12.0B | |
| Change In Working Capital | (1.3B) | 106M | (1.3B) | (258M) | 2.8B | 3.0B | |
| Begin Period Cash Flow | 7.3B | 39.9B | 8.4B | 9.7B | 9.2B | 8.9B | |
| Other Cashflows From Financing Activities | (552M) | (333M) | (674M) | 1.2B | (562M) | (590.1M) | |
| Depreciation | 2.0B | 6.5B | 8.5B | 8.5B | 8.7B | 9.1B | |
| Other Non Cash Items | 3.6B | 8.0B | 4.2B | 6.1B | 8.6B | 9.0B | |
| Capital Expenditures | 552M | 798M | 787M | 695M | 777M | 611.5M | |
| Total Cash From Operating Activities | 13.3B | 17.6B | 22.8B | 24.9B | 22.8B | 12.6B | |
| Change To Account Receivables | (74M) | (929M) | (1.3B) | (1.5B) | 66M | 69.3M | |
| Net Income | 7.9B | 4.6B | 11.5B | 11.8B | 4.9B | 6.3B | |
| Total Cash From Financing Activities | 18.7B | (11.5B) | (19.0B) | (24.8B) | (17.2B) | (16.4B) | |
| End Period Cash Flow | 39.9B | 8.4B | 9.7B | 9.2B | 12.8B | 9.8B | |
| Total Cashflows From Investing Activities | 596M | (37.6B) | (2.3B) | (623M) | (2.0B) | (2.1B) | |
| Sale Purchase Of Stock | (629M) | (978M) | (934M) | (1.5B) | (2.0B) | (2.1B) | |
| Investments | 981M | 114M | (1.4B) | (447M) | (2.0B) | (1.9B) | |
| Change Receivables | (74M) | (929M) | (1.3B) | (1.5B) | (1.3B) | (1.2B) | |
| Net Borrowings | 25.8B | (2.7B) | (8.4B) | (12.4B) | (11.2B) | (10.6B) | |
| Exchange Rate Changes | (39M) | 7M | (5M) | (97M) | (111.6M) | (117.1M) | |
| Dividends Paid | 6.4B | 7.7B | 9.3B | 10.0B | (10.5B) | (10.0B) | |
| Cash And Cash Equivalents Changes | 32.6B | (31.5B) | 1.3B | (483M) | (434.7M) | (413.0M) | |
| Cash Flows Other Operating | 97M | 134M | (197M) | 2.0B | 1.8B | 1.2B | |
| Change To Netincome | 4.8B | 6.4B | 4.0B | 2.6B | 3.0B | 3.4B | |
| Change To Liabilities | (1.1B) | 941M | 338M | 2.1B | 2.5B | 2.6B | |
| Change To Operating Activities | 97M | 134M | (197M) | (264M) | (237.6M) | (225.7M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for AbbVie Stock Analysis
When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.